NASDAQ:CYTK - Cytokinetics Stock Price, Forecast & News

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics, Inc. (NASDAQ:CYTK) posted its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.06. The biopharmaceutical company had revenue of $6.06 million for the quarter, compared to analysts' expectations of $7.80 million. Cytokinetics had a negative net margin of 378.70% and a negative return on equity of 10,351.99%. View Cytokinetics' Earnings History.

Cytokinetics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Cytokinetics.

6 Wall Street analysts have issued 12 month price targets for Cytokinetics' stock. Their forecasts range from $16.00 to $26.00. On average, they expect Cytokinetics' stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 69.8% from the stock's current price. View Analyst Price Targets for Cytokinetics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytokinetics.

News stories about CYTK stock have trended very positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytokinetics earned a daily sentiment score of 3.9 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Cytokinetics.

Cytokinetics saw a increase in short interest in December. As of December 31st, there was short interest totalling 9,400,000 shares, an increase of 6.7% from the December 15th total of 8,810,000 shares. Based on an average daily volume of 840,600 shares, the days-to-cover ratio is currently 11.2 days. Currently, 17.3% of the shares of the stock are sold short. View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include Alkermes (ALKS), Uniqure (QURE), Karuna Therapeutics (KRTX), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), ArQule (ARQL), Zogenix (ZGNX), Epizyme (EPZM), Arena Pharmaceuticals (ARNA), Ra Pharmaceuticals (RARX), Heron Therapeutics (HRTX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Aurinia Pharmaceuticals (AUPH) and Prestige Consumer Healthcare (PBH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Geron (GERN), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX).

Cytokinetics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Mirador Capital Partners LP (0.17%), Louisiana State Employees Retirement System (0.03%), Granite Investment Advisors LLC (0.03%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Robert I Blum and Value Fund L P Biotechnology. View Institutional Ownership Trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and Granite Investment Advisors LLC. Company insiders that have sold Cytokinetics company stock in the last year include Fady Ibraham Malik and Robert I Blum. View Insider Buying and Selling for Cytokinetics.

CYTK stock was acquired by a variety of institutional investors in the last quarter, including Mirador Capital Partners LP and Nisa Investment Advisors LLC. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $12.66.

Cytokinetics has a market capitalization of $747.95 million and generates $31.50 million in revenue each year. The biopharmaceutical company earns $-106,290,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.View Additional Information About Cytokinetics.

The official website for Cytokinetics is http://www.cytokinetics.com/.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]